多肽、蛋白质类药物缓释剂型的研究进展

,,,::,55.1,,,,[7]5.2,,,,,,,,,[811],,,,,(clusterassay)[1112],,,,,,[1],,..,1999,15(10):401.[2],,..,1999202201(3).[3],,,..,1998,33(11):876.[4].2STATISTICA/w5.0.:1998.:,1999:224.[5].2SSPS7.0.:1998.:.1999:184.[6].2MicrocolOrigin.:1998.:,1999:194.[7]JohnNW,TimothyGM,PatrickMOp.Aninformation2intensiveapproachtothemolecularpharmacologyofcancer.Science,1997,275(5298):343.[8]PooleyCL,EdwardsJP,GoldmanME,etal.Discoveryandpre2liminarySARstudiesofanovel,nonsteroidalprogesteronerecep2torantagonistpharmacophore.JMedChem,1998,41:3461.[9]LamKS.Applicationofcombinatoriallibrarymethodsincancerresearchanddrugdiscovery.AnticancerDrugDes,1997,12:145.[10]KennyBA,BushfieldM,Parry2SmithDJ,etal.Theapplicationofhigh2throughputscreeningtonovelleaddiscovery.ProgDrugRes,1998,51:245.[11]StantonDT,MorrisTW,RoychoudhuryS,etal.Applicationofnearest2neighborandclusteranalysesinpharmaceuticalleaddis2covery.JChemInfComputSci,1999,39:21.[12]GaoH,WilliamsC,LabuteP,etal.Binaryquantitativestructure2activityrelationship(QSAR)analysisofestrogenreceptorlig2ands.JChemInfComputSci,1999,39:164.(:1999207227)(200437)::()();:(),;;;,35,DNAParexlpsPhar2maceuticalR&DStatisticalSourceBook,723FDA(FDA),700(),74120003353ChinPharmJ,2000March,Vol.35No.3'1994-2008ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(FDA)[1],,,,,:,[2],,13(LHRH)[3],1,,1.1(implant)1.1.1[4],,,(silastic,),(PDR)NorplantÒ,218,2.4mm,34mm,6,5,1.1.2Alza2070,,,,,,[5],:,1.1.320,:,,2(PLGA)(PLCG),PLGA2070,,(biocomparability),10,,,,[3]ZenicaZoladex,(goserelin)PLGA,1mm,,3.6mg,,,[4]:(),,1.21.2.1,PLGA,,,10,LHRHLHRH10,:122232425262728292102NH2,,(GTH),,LHRH(90min),,;,(LH)(FSH),,,,[67](triptorelin)LHRH,PLGAIpsen,1986,1,(leuprorelin)LHRH,LHRH151,1989,LHRH[89],1(LHRH2A)2,LHRH15,,1,,2,21.2.2,,,841ChinPharmJ,2000March,Vol.35No.320003353©1994-2008ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(leuprorelin)Enantone,7525Lucrin,Lupron,Tap2144SRPLA3(1996)10030DecapeptylPLCG1Ipsen/(triptorelin)5050Ferring2580PLCG1Hoechst(buserelin)752575ZoladexPLCG1ICI(goserelin)5050200144PLCASyntex/South(nafarelin)5050Res.Inst.()2PLGA1(EPO)505022PLGA10(rhIFN2)50507d(IL2)PLGA1150507d7525PLGA1250509d(GM2CSF)PLGA13(rhGH)505030d14PLGA15(somatostatin)5050250d,,,,,,,,(singledosevaccine),WHO(tetannstoxoid,TT)PLGATT,,5050PLAG,(115m),TT(142ngmg-1),;7525PLGA1060m,TT(3ngmg-1),(burstef2fect),311TT,33[16]/mBSA0.3,(EVAC)2EVAC0.3,ABSAEVAC,BSATTH20.5(BSA50mg)PLGA50505.3434kDaSEBPLGA11050502050PLA30100,49kDaMN2rgp120PLGA20100HSDPLGA6535590PLAMN2rgp120PLGA50500.370.5034kDaPLGA0.450.6050501.213.206.2432.1:BSA:;SEB:;MN2rgp120:(HIV21)2,22,2.12(w/o/w2liquiddryingprocess),PLGA(),,(w/o),PVA,(w/o/w),,,,2.2(cryogenicprocess),,-70,,,,,,15%35%,,100%,[14]3,,,94120003353ChinPharmJ,2000March,Vol.35No.3'1994-2008ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.(),,,,,,,2[1].10.,1999,34(1):3.[2],..,1997,24(30):129.[3]KadaH.One2andthree2monthreleaseinjectablemicrospheresoftheLHRHsuperagonistleuprorelinacetate.AdvDrugDeliRev,1997,28:43.[4]PhysicianpsDeskReference49th.MedicalEconomics,1997:2564;2638.[5]JohsonP,Llogd2JonesJG.Drugdeliverysystems.MontvaleNJ.EllisHorwood,1987:139;128.[6]..:,1992:5.[7]FilicoriM.Gonadotropin2releasehormoneagonists,aguidetouseandselection.Drugs,1994,48(1):41;121;139;157.[8].LHRH.,1997,18(2):108.[9],,,..,2000,31(1):15.[10]YangJ,ClelandJL.Factorsaffectingtheinvitroreleaseofre2combinanthumaninterferon2(rhIFN2)fromPLGAmicro2spheres.JPharmSci,1997,86(8):908.[11]ChenL.ApteRN,CohenS.CharacterizationofPLGAmicro2spheresforthecontrolleddeliveryofIL21fortumorim2munotherapy.JControlledRelease,1997,43:261.[12]PettitDK,LawterJR,HuangWJ,etal.Characterizationofpoly(glylcolide2co2DL2lactide)/poly(DL2Lactide)microspheresforcontrolledreleaseofGM2CSF.PharmRes,1997,14(10):1422.[13]JohnsonOL,JaworowiczW,ClelandJL,etal.Thestabilizationandencapsulationofhumangrowthhormoneintobiodegradablemicrospheres.PharmRes,1997,14(6):730.[14]ClelandJL,JonhsonOL,PutneyS,etal.Recombinanthumangrowthhormonepoly(lactic2co2glycolicacid)microspherefor2mulationdevelopment.AdvDrugDeliRev,1997,28:71.[15]Rothen2WeinholdA,BesseghirK,DeZelicouttR,etal.Develop2mentandevaluationinvivoofalong2termdeliverysystemforvaperotide,asomatostatinanalogue.JControlledRelease,1998,52:205.[16]HanesJ,ClelandJL,LangerR.Newadvancesinmicrospherebasedsingle2dosevaccines.AdvDrugDeliRev,1997,28:97.(:1999209209)(300072):,,:,:,,:;;,[13][poly(orthoesters),POE],60,,[45],FDA,,,,,[6]1,,,,(18G),,[7],,,,(surfaceerosion)[8],,,,,2[9],1,2,621,1,42,,,,051ChinPharmJ,2000March,Vol.35No.320003353©1994-2008ChinaAcademicJournalElectronicPublishingHouse.Allrightsreserved.